Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 9/20 | 0.36 |
| ▸ | CES1 | P23141 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7620336 | 0.93 | CES2 (0.50) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL19770805 | 0.89 | FDPS (0.32) | CES2LPAR1LPAR3FAAHFDPS | |
| SCHEMBL8114663 | 0.86 | ARG1 (0.33) | CES2 | |
| SCHEMBL11303168 | 0.85 | LPAR1 (0.36) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL11298075 | 0.85 | LPAR1 (0.36) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL11515807 | 0.85 | CES2 (0.40) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL12396594 | 0.85 | CES2 (0.40) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL10994874 | 0.85 | LPAR1 (0.36) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL16613924 | 0.85 | CES2 (0.40) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL8410340 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-216778775-U | Novel preparation device of (2-oxo-3, 3-difluoro heptyl) dimethyl phosphonate | 南京诺希生物科技有限公司 | 2022-06-21 | — | — | CN | claimed |
| US-7928252-B2 | Prostaglandin synthesis and intermediates for use therein | ALPHORA RESEARCH INC. (CA) | 2011-04-19 | — | — | US | claimed |
| US-20100056807-A1 | PROSTAGLANDIN SYNTHESIS AND INTERMEDIATES FOR USE THEREIN | ALPHORA RESEARCH INC. (CA) | 2010-03-04 | — | — | US | claimed |
| US-20100056808-A1 | PROSTAGLANDIN SYNTHESIS AND INTERMEDIATES FOR USE THEREIN | ALPHORA RESEARCH INC. (CA) | 2010-03-04 | — | — | US | claimed |
| CN-115663287-B | High-pressure-resistant flame-retardant sodium ion electrolyte, preparation method thereof and sodium ion battery | 湖南法恩莱特新能源科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115663287-A | High-pressure-resistant flame-retardant sodium ion electrolyte, preparation method thereof and sodium ion battery | 湖南法恩莱特新能源科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-216778775-U | Novel preparation device of (2-oxo-3, 3-difluoro heptyl) dimethyl phosphonate | 南京诺希生物科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-216778775-U | Novel preparation device of (2-oxo-3, 3-difluoro heptyl) dimethyl phosphonate | 南京诺希生物科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-216778775-U | Novel preparation device of (2-oxo-3, 3-difluoro heptyl) dimethyl phosphonate | 南京诺希生物科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-1981867-B1 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE | R-TECH UENO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9382272-B2 | Methods of making lubiprostone and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2016-07-05 | — | — | US | disclosed |
| CN-102101835-B | Prostaglandin derivative and preparation method of prostaglandin derivative intermediate | WUHAN QIRUI PHARMACEUTICAL CO LTD | 2015-07-22 | — | — | CN | disclosed |
| US-3969379-A | 13,14-Dihydro-16-fluoro prostaglandin A1 analogs | THE UPJOHN COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
| US-3969380-A | 16-Fluoro prostaglandin F2 analogs | THE UPJOHN COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
| US-3969381-A | 13,14-Dihydro-16-fluoro prostaglandin B1 analogs | THE UPJOHN COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
| US-3969376-A | 13,14-Dihydro-16-fluoro prostaglandin E1 analogs | THE UPJOHN COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
| US-3969378-A | 16-Fluoro prostaglandin A2 analogs | THE UPJOHN COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
| US-3969377-A | 16-Fluoro prostaglandin E1 analogs | THE UPJOHN COMPANY (US) | 1976-07-13 | — | — | US | disclosed |
| US-3962293-A | 13,14-Dihydro-16-fluoro prostaglandin F1 | THE UPJOHN COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3931279-A | 5-Oxa prostaglandin F2.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056807-A1 | PROSTAGLANDIN SYNTHESIS AND INTERMEDIATES FOR USE THEREIN | ALOX5, PTGES, PTGIS | CES2 3592/4885LPAR1 63/4885LPAR3 125/4885 |
| US-20100056808-A1 | PROSTAGLANDIN SYNTHESIS AND INTERMEDIATES FOR USE THEREIN | ALOX5, PTGES, ALOX15 | CES2 3594/4885LPAR1 67/4885LPAR3 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.